Bullish Options Activity on Nevro Corp Surges After Better Fundamentals

 Bullish Options Activity on Nevro Corp Surges After Better Fundamentals

In today’s session Nevro Corp (NVRO) registered an unusually high (216) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the November, 2016 call, expecting serious NVRO increase. With 216 contracts traded and 4424 open interest for the Nov, 16 contract, it seems this is a quite bullish bet. The option with symbol: NVRO161118C00100000 closed last at: $2.1 or 47.5% down. About 299,269 shares traded hands. Nevro Corp (NYSE:NVRO) has risen 32.33% since April 4, 2016 and is uptrending. It has outperformed by 31.24% the S&P500.

Analysts await Nevro Corp (NYSE:NVRO) to report earnings on November, 14. They expect $-0.39 EPS, up 44.29% or $0.31 from last year’s $-0.7 per share. After $-0.27 actual EPS reported by Nevro Corp for the previous quarter, Wall Street now forecasts 44.44% negative EPS growth.

Nevro Corp (NYSE:NVRO) Ratings Coverage

Out of 9 analysts covering Nevro Corp (NYSE:NVRO), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. $110 is the highest target while $48 is the lowest. The $82.33 average target is -6.96% below today’s ($88.49) stock price. Nevro Corp has been the topic of 12 analyst reports since August 13, 2015 according to StockzIntelligence Inc. On Tuesday, March 29 the stock rating was initiated by Northland Capital with “Market Perform”. The stock of Nevro Corp (NYSE:NVRO) earned “Overweight” rating by JP Morgan on Tuesday, August 9. The firm has “Overweight” rating by PiperJaffray given on Friday, July 22. JMP Securities maintained the shares of NVRO in a report on Tuesday, August 9 with “Market Outperform” rating. On Friday, September 25 the stock rating was initiated by BMO Capital Markets with “Outperform”. William Blair initiated Nevro Corp (NYSE:NVRO) on Tuesday, July 19 with “Outperform” rating. The rating was initiated by Piperjaffray on Friday, July 22 with “Overweight”.

According to Zacks Investment Research, “Nevro Corp. is a medical device company. It engages in developing and commercializing a neuromodulation platform for the treatment of chronic pain. The Company provides pain relief to the customers suffering from low back pain and types of chronic pains. Nevro has developed and commercialized the Senza (R) spinal cord stimulation (SCS) system for the treatment of chronic pain. Senza, HF10, Nevro and the Nevro logo are trademarks of the company. Nevro Corp. is headquartered in Menlo Park, California.”

Nevro Corp. is a medical device company. The company has a market cap of $2.31 billion. The Firm has developed and commercialized a neuromodulation platform for the treatment of chronic pain. It currently has negative earnings. The Company’s Senza system is a spinal cord stimulation system that delivers its HF10 therapy.

NVRO Company Profile

Nevro Corp., incorporated on October 4, 2006, is a medical device company. The Firm has developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is a spinal cord stimulation (SCS) system that delivers its HF10 therapy. HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy offers back pain relief in addition to leg pain relief. HF10 therapy also provides pain relief without paresthesia. HF10 therapy offers benefits to patients, physicians and hospitals.

More recent Nevro Corp (NYSE:NVRO) news were published by: Fool.com which released: “Why Nevro Corp. Is Up Big Today” on August 09, 2016. Also Prnewswire.com published the news titled: “Publication of Two-Year SENZA-RCT Results in Neurosurgery Demonstrates …” on September 06, 2016. Prnewswire.com‘s news article titled: “Nevro Receives FDA Approval for New Surgical Leads for the Senza® Spinal Cord …” with publication date: April 15, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment